Drug Profile
AB 111021
Alternative Names: AB 1110 21; AB-1110-21/WREALatest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator AlphaBeta Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Pain in United Kingdom
- 16 May 2016 Preclinical trials in Pain in United Kingdom (unspecified route) before May 2016